scholarly journals Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas

2015 ◽  
Vol 98 (3) ◽  
pp. 446-454 ◽  
Author(s):  
Yuwen Xie ◽  
Peizhi Zong ◽  
Weiwei Wang ◽  
Dong Liu ◽  
Bingcheng Li ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Tumor Suppressor ◽  
Clinical Stage ◽  
Soft Tissue Sarcomas ◽  
Potential Tumor Suppressor

scholarly journals Should metastatic lymph nodes be considered at the same clinical stage as distant metastasis in soft tissue sarcomas?

2021 ◽  
Vol 26 ◽  
pp. 100268
Author(s):  
Dorian Yarih Garcia-Ortega ◽  
Alethia Alvarez-Cano ◽  
Miguel Angel Clara-Altamirano ◽  
Karla Susana Martín-Tellez ◽  
Claudia Haydee Sarai Caro-Sánchez ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Lymph Nodes ◽  
Distant Metastasis ◽  
Clinical Stage ◽  
Soft Tissue Sarcomas ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

Abstract 4183: Modeling soft tissue sarcomas by conditional inactivation of p53 and Rb tumor suppressor genes

2010 ◽  
Author(s):  
Jinhyang Choi ◽  
David M. Roy ◽  
Stephen J. Curtis ◽  
Andrea Flesken-Nikitin ◽  
Chang-il Hwang ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Tumor Suppressor ◽  
Tumor Suppressor Genes ◽  
Soft Tissue Sarcomas ◽  
Suppressor Genes ◽  
Conditional Inactivation

scholarly journals CT and MRI radiomics of bone and soft-tissue sarcomas: a systematic review of reproducibility and validation strategies

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Salvatore Gitto ◽  
Renato Cuocolo ◽  
Domenico Albano ◽  
Francesco Morelli ◽  
Lorenzo Carlo Pescatori ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Model Validation ◽  
Clinical Stage ◽  
Intraclass Correlation ◽  
Model Development ◽  
Soft Tissue Sarcomas ◽  
Research Area ◽  
Preclinical Research ◽  
Internal Validation ◽  
Ct And Mri

Abstract Background Feature reproducibility and model validation are two main challenges of radiomics. This study aims to systematically review radiomic feature reproducibility and predictive model validation strategies in studies dealing with CT and MRI radiomics of bone and soft-tissue sarcomas. The ultimate goal is to promote achieving a consensus on these aspects in radiomic workflows and facilitate clinical transferability. Results Out of 278 identified papers, forty-nine papers published between 2008 and 2020 were included. They dealt with radiomics of bone (n = 12) or soft-tissue (n = 37) tumors. Eighteen (37%) studies included a feature reproducibility analysis. Inter-/intra-reader segmentation variability was the theme of reproducibility analysis in 16 (33%) investigations, outnumbering the analyses focused on image acquisition or post-processing (n = 2, 4%). The intraclass correlation coefficient was the most commonly used statistical method to assess reproducibility, which ranged from 0.6 and 0.9. At least one machine learning validation technique was used for model development in 25 (51%) papers, and K-fold cross-validation was the most commonly employed. A clinical validation of the model was reported in 19 (39%) papers. It was performed using a separate dataset from the primary institution (i.e., internal validation) in 14 (29%) studies and an independent dataset related to different scanners or from another institution (i.e., independent validation) in 5 (10%) studies. Conclusions The issues of radiomic feature reproducibility and model validation varied largely among the studies dealing with musculoskeletal sarcomas and should be addressed in future investigations to bring the field of radiomics from a preclinical research area to the clinical stage.

Neuroradiology Manifestations of Li-Fraumeni Syndrome: Epidemiology, Genetics, Imaging Findings, and Management

Neurographics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 228-235
Author(s):  
S. Naganawa ◽  
T. Donohue ◽  
A. Capizzano ◽  
Y. Ota ◽  
J. Kim ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Soft Tissue Sarcomas ◽  
Suppressor Gene ◽  
Imaging Findings ◽  
Li Fraumeni Syndrome ◽  
Increased Risk ◽  
Li Fraumeni ◽  
Risk Of Cancer

Li-Fraumeni syndrome is a familial cancer predisposition syndrome associated with germline mutation of the tumor suppressor gene 53, which encodes the tumor suppressor p53 protein. Affected patients are predisposed to an increased risk of cancer development, including soft-tissue sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma, among other malignancies. The tumor suppressor gene TP53 plays an important, complex role in regulating the cell cycle, collaborating with transcription factors and other proteins. The disruption of appropriate cell cycle regulation by mutated TP53 is considered to be the cause of tumorigenesis in Li-Fraumeni syndrome. Appropriate surveillance, predominantly by using MR imaging, is used for early malignancy screening in an effort to improve the survival rate among individuals who are affected. Patients with Li-Fraumeni syndrome are also at increased risk for neoplasm development after radiation exposure, and, therefore, avoiding unnecessary radiation in both the diagnostic and therapeutic settings is paramount. Here, we review the epidemiology, genetics, imaging findings, and the current standard surveillance protocol for Li-Fraumeni syndrome from the National Comprehensive Cancer Network as well as potential treatment options.Learning Objective: Describe the cause of second primary malignancy among patients with Li-Fraumeni syndrome.

LOCAL RECURRENCES AFTER THE TREATMENT OF SOFT TISSUE MALIGNANT FIBROUS HISTIOCYTOMA (UNCLASSIFIEDPLEOMORPHIC SARCOMA) OF THE LIMBS

2019 ◽  
Vol 72 (8) ◽  
pp. 1523-1526
Author(s):  
Oleksandr O. Lytvynenko ◽  
Volodymyr F. Konovalenko ◽  
Anton Yu. Ryzhov
Keyword(s):  
Soft Tissue ◽  
Malignant Fibrous Histiocytoma ◽  
Fibrous Histiocytoma ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Primary Treatment ◽  
Radical Excision ◽  
Local Recurrences ◽  
Results Of Treatment

Introduction: The treatment of patients with malignant fibrous histiocytoma as well as other soft tissue sarcomas is not sufficiently effective up to date, and has largely changed and reflects the alterations, occurred in oncology as a whole. The number of amputation decreased over the last 10-15 years. Some researchers associate the improvement of treatment outcomes with the development of combined and complex methods. The aim of the study is an improvement of the results of treatment of patients with soft tissue malignant histiocytoma on the basis of determination of factors, influencing local recurrence development. Materials and methods: The basis of our study was a comprehensive analysis of examination and treatment results of 130 patients with MFH of the soft tissue of limbs, of them in 84 patients (64.6%) the recurrences developed. The group included 45 (53.6%) males and 39 (46.4%) females. The major part of patients – 82.1% (60 patients) were older than 40 years. Results and conclusions: The number of recurrences after the treatment in general surgical facilities is 86.9%, whereas in the patients after the treatment in the specialized oncological facilities this figure is twice lower (40%). The characteristic of the medical facility where the patient receives his/her primary treatment largely affects the development of local recurrences, patients’ quality of life and overall survival rates. The surgical method remains the leading modality in the treatment of MFH of ST. Wide and radical excision of tumors in the specialized oncological facilities allows achieving better survival outcomes of the patients.

Sign in / Sign up

Export Citation Format

Share Document